EATRIS Quality Initiative

The EATRIS Quality Initiative (EQI) is an umbrella structure for EATRIS activities addressing reproducibility, best practice guidelines, benchmarking, standards and reference materials. Significant contributions in this field can only be achieved by collaborating on international and global scale. By involving EATRIS member facilities in international consortia which address data quality and reproducibility in translational medicine, the EQI aims to improve overall scientific conduct while simultaneously helping increase credibility and visibility of the EATRIS community as go-to-provider of high-quality data. EATRIS, with its 110+ member-facilities, is well-suited to help tackle some of the challenges in translational medical research, for example by organising or participating in multi-site benchmarking studies.

Examples of active participation in international efforts are guideline and best practice development and technical benchmarking in the fields of drug screening, DNA and RNA sequencing, and exploration of use of ctDNA standards in clinical setting.

The EQI is continuously looking for opportunities to join and support international efforts. Also, we are always open for suggestions for new projects that we can support. Please note, however, that the EQI is not a funding body.

Do get in contact if you are part of a project which fits the criteria above so that we can showcase your work as part of the EQI portfolio. We would also be keen to hear from you if you have a new idea for a project that could fit the EQI. Please contact Andreas Scherer at or via the details below.

Selected publications related to the EQI:

  1. Deveson et al. (2021). Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. Nature Biotechnology.
  2. Erdbrügger et al. (2021). Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles. Journal of Extracellular Vesicles.
  3. Gong et al. (2021). Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions. Genome Biology, 22, 109.
  4. Jones et al. (2021). A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency. Genome Biology, 22, 111.